Background-Pulmonary hypertension as a frequent complication of left heart disease (PH-LHD) is characterized by lung endothelial dysfunction and vascular remodeling. Although PH-LHD contributes to morbidity and mortality in heart failure, established therapies for PH-LHD are lacking. We tested the effect of chronic sildenafil treatment in an experimental model of PH-LHD. Methods and Results-In Sprague-Dawley rats, PH-LHD was induced by supracoronary aortic banding. Oral sildenafil treatment (60 mg/kg daily) was initiated after 7 days, and lung endothelial function (nϭ5), vascular remodeling, and right ventricular function (nϭ11 each) were analyzed 9 weeks after banding. As compared with sham-operated controls, aortic banding induced pulmonary hypertension and lung endothelial dysfunction evident as lack of endothelial nitric oxide production and endothelium-dependent vasodilation. These changes were associated with an increased pulmonary vascular resistance, medial thickening, and biventricular cardiac hypertrophy. Sildenafil treatment largely attenuated these pathological changes and was not associated with detectable adverse effects pertinent to lung vascular barrier function, edema formation, or systemic hemodynamics. Conclusions-Our data identify sildenafil as a promising therapy for PH-LHD. In light of its documented protective effects at the myocardial level in heart failure, sildenafil presents a particularly attractive strategy in that it simultaneously targets cardiac remodeling and secondary PH-LHD. (Circ Heart Fail. 2011;4:198-206.) 
PAH. 8 On the basis of the common pathological features of PAH and PH-LHD, we speculated that sildenafil may be equally beneficial in PH-LHD, a notion that is supported by small clinical pilot trials. In patients with CHF, acute administration of sildenafil selectively reduced pulmonary arterial pressure (PAP), increased peak VO 2 during exercise, 9 and improved overall exercise capacity. 10 Chronic sildenafil treatment ameliorated exercise capacity and quality of life and improved aerobic efficiency in patients with PH-LHD. 11, 12 Although these data have in part been attributed to the beneficial effects of sildenafil on cardiac remodeling and skeletal muscle perfusion, they may similarly attest to a therapeutic potential for sildenafil in PH-LHD. Yet, a comprehensive analysis of the effects of sildenafil on the pulmonary vasculature in CHF is thus far lacking. Here, we analyzed the effects of chronic sildenafil on lung endothelial function, pulmonary vascular remodeling, and RV function in an experimental model of PH-LHD. 13, 14 Methods A detailed Methods section is provided in the online-only Data Supplement.
Experimental Design
CHF was induced in male Sprague-Dawley rats (102Ϯ10 g body weight) by supracoronary aortic banding. 13, 14 A titanium clip with a residual open diameter of 0.8 mm was implanted across the ascending aorta distal to the origins of the coronary arteries. Sham-operated rats served as controls. Sildenafil treatment (60 mg/kg body weight daily p.o. in the drinking water) was initiated 1 week after aortic banding and continued for 8 weeks until PH and lung vascular adaptation were assessed. Comparable dosages were previously reported to be safe and effective in rats. 15 
Cardiac Function and Hypertrophy
Transthoracic echocardiography was performed as described. 14 RV end-diastolic diameter (RVEDD) and area and left ventricular (LV) area and ejection fraction (LVEF) were measured. Tricuspid annular plane systolic excursion (TAPSE) and pulmonary artery acceleration time (PAAT) were quantified as indicators of RV systolic longitudinal function and PH. RV weight and the weight of the LV and septum (LVϩS) were determined relative to body weight.
Hemodynamics
Arterial pressure (AP), central venous pressure, PAP, left atrial pressure (LAP), mixed venous oxygen saturation (SvO 2 ), and aortic flow were measured via implanted catheters and an ultrasonic flow probe, and systemic vascular resistance (SVR) and PVR were calculated. 13, 14 To assess lung vascular biomechanics in detail, we analyzed pressure-flow curves in the isolated perfused lung. 16 Intrinsic lung vascular resistance, R 0 , that is, the resistance that would exist if the vessels were at their respective diameter at zero vascular pressure, and the vascular distensibility factor ␣ were calculated. 16
Histostereology and Biochemistry
Lungs were fixed, paraffin-embedded, sectioned, and stained with hematoxylin and eosin. Blinded stereological analysis of mean wall thickness of lung arterial vessels (diameter, 100 to 1000 m) was performed. 17 Lung phosphodiesterase-5 expression was analyzed by Western blot. In aortic blood samples, plasma concentrations of sildenafil and its main metabolite N-desmethyl-sildenafil were determined by high-performance liquid chromatography coupled to tandem mass spectrometry and those of cyclic guanosine 3Ј,5Јmonophosphate (cGMP) by enzyme-linked immunosorbent assay.
Endothelial Function
Endothelial nitric oxide (NO) production, endothelium-dependent vasodilation, and endothelial barrier function were assessed in isolated, perfused rat lungs. 18, 19 Dose-dependent endothelial NO production in response to acetylcholine (ACh) was measured by fluorescence imaging of the NO-sensitive dye DAF-FM. 18 Endothelium-dependent vasodilation was assessed as dose-dependent reduction in PAP (⌬PAP) in response to ACh in lungs preconstricted by a continuous infusion of U46619 (50 pmol ⅐ min Ϫ1 ). 19 Lung vascular filtration coefficient (K f ) was measured, 18 and lung edema was evaluated by measurement of wet-to-dry lung weight ratios.
Statistical Analysis
Data are presented as meanϮ SEM. Group sizes are nϭ11 for echocardiographic, histostereological, and biochemical analyses. Western blots were replicated in triplicate. Hemodynamics and endothelial function were assessed in groups of nϭ5 each. Values of several groups were compared by Mann-Whitney U tests and Kruskal-Wallis test for 2 or more independent groups. Spearman coefficient of correlation (r s ) was calculated, and nonlinear regression analyses were performed using SigmaPlot software. Statistical significance was assumed at PϽ0.05.
Results

Plasma Levels of Sildenafil and N-Desmethyl-Sildenafil
In plasma samples from untreated rats, sildenafil and its metabolite N-desmethyl-sildenafil were always below the limit of quantification (Ͻ2 nmol/L). Of the sildenafil-treated rats, 22.7% and 50% had measurable plasma concentrations of sildenafil or N-desmethyl-sildenafil, respectively, with considerable variation between animals ( Figure 1A ).
Ventricular Hypertrophy and Function
Within 9 weeks, rats with aortic banding showed significant increases in RV and LV weight ( Figure 1B ,C), whereas body weights of CHF and control animals did not differ (355Ϯ7 g in control, 352Ϯ6 g in CHF rats). Sildenafil treatment markedly attenuated both RV and LV hypertrophy ( Figure 1B and 1C). The notion that sildenafil may have protective effects on RV function was substantiated in echocardiographic measurements. As shown in representative B-mode images ( Figure 2A ) and group data ( Figure 2B through 2G), aortic banding resulted in marked RV dilation, evident as increased end-diastolic area and diameter, that was associated with signs of PH and impaired RV systolic longitudinal function as indicated by reduced PAAT and TAPSE, respectively. Sildenafil reversed echocardiographic signs of RV dilation and PH at large and increased TAPSE. LV end-diastolic area and LVEF did not differ between groups in line with the characteristics of diastolic heart failure with preserved ejection fraction.
Hemodynamics
As compared with sham-operated controls, mean PAP was approximately 7.5 mm Hg higher in CHF rats ( Figure 3A ). This increase was only in part attributable to a congestive "passive" elevation in lung vascular pressures, evident as Ϸ2.4 mm Hg increase in LAP ( Figure 3B ), but similarly caused by a "reactive" increase in PVR. Sildenafil attenuated PH and reduced PVR ( Figure 3C ) without causing a significant reduction in LAP. Mean arterial pressure ( Figure 3D ) and aortic flow ( Figure 3E ) did not differ between CHF and control animals and were not affected by sildenafil.
Lung Vascular Biomechanics
As compared with controls, isolated lungs from untreated CHF rats showed a marked reduction in vascular distensibility ( Figure 4A ) and a concomitant increase in intrinsic vascular resistance ( Figure 4B ) consistent with the observed increase in PVR. Sildenafil largely reversed the effects of CHF on lung vascular biomechanics.
Lung Vascular Remodeling
Considerable lung vascular remodeling was evident in CHF rats as medial wall thickening in small (inner diameter Ͻ150 m), medium (diameter, 150 to 250 m), and large pulmonary arteries (diameter, 250 to 1000 m). Sildenafil prevented vascular remodeling in small and medium arteries and mitigated medial thickening in large arteries ( Figure 5 ).
PDE5 Expression and cGMP Plasma Levels
As demonstrated by representative immunoblots ( Figure 6A ) and group data ( Figure 6B ), PDE5 expression in lung homogenate was downregulated by Ϸ50% in CHF as compared with control rats. To test whether sildenafil could still effectively increase cGMP concentrations, we measured cGMP levels in aortic plasma. Aortic cGMP levels in CHF rats were significantly lower as compared with controls ( Figure 6C ). Sildenafil not only restored aortic cGMP levels but almost doubled them as compared with untreated controls. Mean wall thickness over all vessel calibers correlated inversely with aortic cGMP levels and decreased exponentially with increasing concentrations of cGMP ( Figure 6D ). Of note, mean wall thickness remained virtually unchanged over a wide concentration range of cGMP from 20 to 50 pmol/mL but increased drastically when cGMP levels approached 10 pmol/mL or less.
Lung Endothelial Function
Fluorescence imaging of DAF-FM-loaded endothelial cells identified a marked increase in NO production in response to ACh in pulmonary microvessels of sham-operated rats ( Figure 7B ).
To verify the notion that sildenafil may preserve endothelial function in CHF, we measured the pulmonary pressure response to ACh in preconstricted lungs. In lungs of sham rats, ACh caused a dose-dependent decrease in PAP ( Figure  7C ) that was completely abrogated in CHF lungs. In line with the reconstitution of endothelial NO synthesis in real-time imaging experiments, sildenafil largely restored the pulmonary vasodilatory response to ACh.
Lung Vascular Barrier Function
Vascular permeability, quantified as filtration coefficient K f , was reduced in lungs from CHF rats as compared with sham animals ( Figure 8A ). This adaptive response partially compensated for the chronic elevation in lung hydrostatic pressure, which therefore resulted only in moderate lung edema as indicated by a slight increase in wet-to-dry lung weight ratio ( Figure 8B ). Sildenafil further strengthened lung vascular barrier function as demonstrated by an even lower K f , and this effect was associated with a reduction in lung edema ( Figure  8A and 8B). Changes in lung water content were inversely paralleled by respective changes in SvO 2 , suggesting that CHF impaired and sildenafil restored tissue oxygenation ( Figure 8C ).
Discussion
In the present study, we propose long-term oral sildenafil as a novel strategy for the treatment of PH-LHD. In a rat model of CHF after aortic banding, sildenafil attenuated PH, RV hypertrophy, and dysfunction. This effect was not solely attributable to an attenuation of LV diastolic failure but likewise to the prevention of lung vascular remodeling and the restoration of endothelial function, resulting in a normalization of PVR.
PH With Left Heart Disease
Although PH-LHD develops in the majority of patients with CHF, 1,2 it has received far less attention than PAH with respect to pathomechanistic, epidemiological, or therapeutic studies. 20 The past decades have witnessed a rapid advance in the treatment of PAH, with the clinical introduction of endothelin-1 receptor antagonists, prostacyclin analogs, and the phosphodiesterase inhibitor sildenafil. 21 In consideration of the common pathological features of PAH and PH-LHD, it seems conceivable that some of these interventions may also provide clinical benefit in patients with PH-LHD. Due to its capacity to attenuate cardiac hypertrophy and remodeling in severe heart failure, 22 sildenafil presents a particularly attractive candidate for the treatment of PH-LHD.
In the present study, we analyzed the effects of chronic sildenafil treatment in a preclinical model of CHF that features the typical characteristics of PH-LHD, for example, RV hypertrophy, elevated PVR, vascular remodeling, endothelial dysfunction, and increased vessel tone. 13, 14 Notably, aortic flow, systemic arterial pressure, and LVEF are normal in these animals. The model therefore reflects the clinical picture of heart failure with preserved ejection fraction, a category of heart failure that is attributed to abnormalities in diastolic rather than systolic ventricular function 23 and associated with a high incidence of PH in patients. 2 The observed beneficial effects of sildenafil on pulmonary hemodynamics, endothelial function, and vascular remodeling suggest a direct effect of sildenafil on the pulmonary vasculature. In addition, improvement of LV diastolic function as suggested by the attenuation of LV hypertrophy can be expected to have contributed to the protective effect of sildenafil on pulmonary structure and function. Sildenafil has been shown to mitigate LV remodeling in severe cardiac failure by targeting specific maladaptive hypertrophy signaling cascades. 22, 24 Yet, sildenafil does not exert direct effects on functionally compensated LV hypertrophy, as these pathological signaling cascades are little activated. 24 The observed reduction in LV mass in the treatment group suggests that sildenafil may also attenuate marked LV hypertrophy in diastolic heart failure with preserved EF, a notion that warrants further study given the current evaluation of sildenafil for the clinical treatment of diastolic heart failure. Data are from nϭ11 rats each; *PϽ0.05 versus sham, #PϽ0.05 versus CHF. D, Mean vascular wall thickness of pulmonary arterioles was plotted against plasma cGMP concentration of the respective animal in sham operated, banded, and sildenafil-treated banded rats (nϭ11 each). Data were fitted to a 3-parameteric exponential decay by nonlinear regression analysis (r 2 ϭ0.93, PϽ0.05). Inverse correlation was tested by Spearman coefficient of correlation (r s ϭϪ0.687, PϽ0.001).
Lung Vascular Remodeling
Medial hypertrophy of muscular pulmonary arteries is a frequent finding in severe CHF. 4 This "remodeling" of the vascular wall consolidates PH and contributes critically to the increased PVR in CHF patients. In the current study, considerable vascular remodeling was evident in small, mediumsized, and large pulmonary arteries and associated with a concomitant increase in PVR. Chronic sildenafil treatment attenuated medial hypertrophy in large arteries and completely prevented vascular remodeling in medium-sized and small arteries. This finding is in line with the welldocumented antiproliferative effect of sildenafil, 22, 25 which has been attributed to mechanisms including stimulation of the cGMP-dependent protein kinase and regulator of G protein signaling 2 pathway, 25 to upregulation of mitogen-activated protein kinase phosphatase-1 and inhibition of extra- , and sildenafil-treated banded rats (CHFϩsil). Dose-response curves were constructed from 4-parametric logistic curve fits. Data are from nϭ5 rats each; *PϽ0.05 versus sham, #PϽ0.05 versus CHF. C, Group data show endothelium-dependent vasorelaxation response to ACh in isolated, perfused rat lungs preconstricted by U46619 (50 pmol/min). Vasorelaxation was determined as dose-dependent pressor response and is expressed as reduction in pulmonary arterial pressure (⌬PAP) relative to the respective vehicle control. Dose-responses were constructed from four-parametric logistic curve fits. Data are from nϭ5 rats each; *PϽ0.05 versus sham, #PϽ0.05 versus CHF. cellular signal-regulated kinase 1/2 phosphorylation, 26 as well as to inhibition of reactive oxygen species generation and RhoA/Rho kinase activation. 27 Although the prevention of lung vascular remodeling by sildenafil was paralleled by a complete normalization of PVR, CHF-induced pulmonary hypertension was only partially reversed, and PAP remained elevated by Ϸ2 mm Hg (without reaching PϽ0.05), reflecting the persistent increase in LAP as a consequence of the sustained banding.
Sildenafil is most prominently known for its inhibitory effect on PDE5. PDE5 is markedly upregulated in lungs and right ventricles of patients with PAH or congenital heart disease, 28, 29 but its expression was reduced in lung endothelial cells of rats with aortic banding. Our finding is in line with the reported decrease in myocardial PDE5 expression in pacing-induced heart failure 30 and may indicate a differential regulation of PDE5 expression in PH and ventricular remodeling of different etiologies. In addition to blocking PDE5, sildenafil also blocks PDE1, and, like PDE5 blockers, specific PDE1 inhibition can reverse lung vascular remodeling and RV hypertrophy in rodent models of PAH. 31 Yet, in contrast to the cGMP-specific activity of PDE5, PDE1 hydrolyzes both cAMP and cGMP. 22 The reported IC 50 of sildenafil for PDE5 in rats is 3.4 nmol/L, 32 whereas IC 50 for PDE1 can be estimated as 250 to 300 nmol/L, based on available data in humans. 33 In the present study, plasma concentrations of sildenafil and its active metabolite N-desmethyl-sildenafil were well below the IC 50 for PDE1 in sildenafil-treated rats. Yet, because of the approximately 10ϫ faster elimination of sildenafil in rats as compared with humans, 34 considerably higher sildenafil concentrations may have been achieved immediately after drug uptake with the drinking water that may have sufficed to inhibit PDE1 at least temporarily. The extremely short plasma half-life of sildenafil in rats in combination with individual differences in the time lag between the last oral sildenafil uptake and the actual experiment is also likely to account for the large variability in plasma concentrations.
As compared with controls, plasma cGMP levels in aortic blood of CHF rats were markedly reduced. Given the short half-life of cGMP in plasma, this finding probably signifies endothelial dysfunction in the pulmonary rather than the systemic circulation. Aortic cGMP levels correlated inversely with vessel wall thickness, suggesting that inhibition of cGMP hydrolysis may be critically involved in the detected antiremodeling effect. Remarkably, this inverse relationship appears to be pathognomonic for PH-LHD: On the one hand, patients or animal models with PAH consistently show supranormal urinary or plasma cGMP levels. 35, 36 LHD without pulmonary involvement, on the other hand, likewise results in elevated cGMP plasma levels in peripheral blood due to increased circulating levels of natriuretic peptides. 37 In contrast, severe heart failure with PH causes natriuretic peptide resistance, in that pulmonary cGMP release no longer matches the transpulmonary extraction of natriuretic peptides, 38, 39 thus resulting in subnormal cGMP levels in aortic blood. In line with this notion, pulmonary cGMP release was recently shown to correlate inversely with pulmonary vascular resistance in patients with heart failure. 39 The fact that wall thickness remains unchanged over a large range of cGMP concentrations but increases steeply at very low cGMP levels implies that aortic cGMP concentrations may present a potential biomarker for lung vascular remodeling in CHF. In the present study, a cutoff value of 24 pmol/mL for aortic cGMP levels would identify banded rats with a sensitivity of 100% and a specificity of 36.4%. The area under the respective receiver operating characteristic curve (online-only Data Supplement Figure 1) is 0.756. Provided that sensitivity and specificity would be similar in patients, cGMP levels in aortic blood obtained, for example, during left heart catheterization, may help to differentiate PH-LHD from PAH patients on the one, and patients with LHD without pulmonary involvement on the other side. PH-LHD could be effectively excluded in patients with normal or supranormal aortic cGMP levels, whereas those with lower values would require further diagnostic evaluation.
Lung Endothelial Dysfunction
Although restoration of endothelial-derived NO synthesis may present a particularly promising strategy in PH-LHD based on the demonstrated inverse relationship between cGMP and vascular remodeling, therapeutic strategies targeting lung endothelial function in CHF are lacking. In line with previous data, 40, 41 marked lung endothelial dysfunction was evident in CHF rats. Lung endothelial function was at large preserved by sildenafil and may contribute relevantly to its beneficial properties in PH-LHD by acting in addition to or in conjunction with its antiproliferative effects. Notably, preservation of endothelial function may potentiate the direct effect of sildenafil in that inhibition of cGMP hydrolysis will coincide with enhanced NO-triggered cGMP synthesis. To our knowledge, the present study is the first to directly demonstrate a protective effect of sildenafil on lung endothelial function, a finding that is in line with previous reports that sildenafil may improve endothelial function in the systemic circulation. 42 Several mechanisms may account for the suppression of endothelial dysfunction by sildenafil, in that sildenafil can restore the expression of endothelial NO synthase, 43 promote its posttranslational activation by stimulating Akt-dependent endothelial NO synthase phosphorylation, 44 and endothelial Ca 2ϩ influx, 45 and inhibit Nox2 expression and superoxide production. 46 As lung endothelial dysfunction in the aortic banding model results primarily from increased ␤-actin expression and subsequent F-actin polymerization, cGMP-dependent activation of vasodilatorstimulated phosphoprotein and subsequent inhibition of actin filament formation may present a particularly intriguing mechanism by which sildenafil may restore endothelial function in this specific setting. 47
Lung Vascular Barrier Function
In CHF, lung microvessels are constantly exposed to elevated hydrostatic pressures and adapt by thickening of the capillary wall and a concomitant silencing of proedematous signaling pathways. 48 Although attenuation of medial proliferation and preservation of endothelial NO synthesis are declared therapeutic targets in PH-LHD, prevention of structural remodeling and endothelial adaptation at the level of alveolar capil-laries may promote barrier failure and alveolar flooding. The use of vasodilators in PH-LHD has also been viewed critically in that opening of precapillary sphincters may increase capillary pressure and thus escalate edema formation. 49 We showed that sildenafil decreases K f in CHF lungs and thus strengthens the microvascular barrier, attenuates lung edema, and improves systemic oxygenation. This barrier-protective effect of sildenafil is consistent with our previous observation that cGMP signaling negatively regulates microvascular barrier failure and that sildenafil attenuates hydrostatic edema formation. 18
Clinical Implications
Our results identify sildenafil as a promising strategy to attenuate lung vascular remodeling and RV hypertrophy in patients with left heart disease and at risk for PH-LHD. The lack of systemic hemodynamic effects of sildenafil is particularly noteworthy in consideration of the catastrophic results from a series of clinical trials that addressed the effectiveness of systemic vasodilators in CHF and at large resulted in increased patient morbidity and/or mortality. 50 Based on its Food and Drug Administration approval for the treatment of PAH, sildenafil may be rapidly exploitable as novel therapy in PH-LHD. Importantly, sildenafil presents a particularly attractive strategy in this context because of its concomitant beneficial effects on the myocardium in severe CHF 22, 25 and its current clinical evaluation in diastolic heart failure in the National Institutes of Health-sponsored "RELAX" trial (NCT00763867). Sildenafil may provide a dual protective effect in CHF in that it reverses cardiac hypertrophy and remodeling while simultaneously attenuating PH-LHD.
